Research ArticleCANCER

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment

See allHide authors and affiliations

Science Advances  04 Jun 2021:
Vol. 7, no. 23, eabg2697
DOI: 10.1126/sciadv.abg2697

Article Information

vol. 7 no. 23

PubMed: 
Online ISSN: 
History: 
  • Received for publication December 21, 2020
  • Accepted for publication April 19, 2021
  • .

Author Information

  1. Jiye Liu1,,
  2. Teru Hideshima1,,
  3. Lijie Xing1,2,
  4. Su Wang3,,
  5. Wenrong Zhou4,
  6. Mehmet K. Samur1,5,
  7. Tomasz Sewastianik6,7,
  8. Daisuke Ogiya1,§,
  9. Gang An8,
  10. Shaobing Gao9,
  11. Li Yang10,
  12. Tong Ji11,
  13. Giada Bianchi12,
  14. Kenneth Wen1,
  15. Yu-Tzu Tai1,
  16. Nikhil Munshi1,
  17. Paul Richardson1,
  18. Ruben Carrasco6,13,
  19. Yong Cang14 and
  20. Kenneth C. Anderson1,*
  1. 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  2. 2Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.
  3. 3Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
  4. 4Oncology and Immunology Unit, Research Service Division, WuXi AppTec (Shanghai) Co., Ltd., Shanghai 200131, China.
  5. 5Department of Biostatistics and Computational Biology, Harvard T.H. Chan School of Public Health, Boston, 02115 MA, USA.
  6. 6Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  7. 7Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw 02776, Poland.
  8. 8State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300020, China.
  9. 9The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
  10. 10Multiple Myeloma Treatment Center and Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
  11. 11Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310020, China.
  12. 12Division of Hematology, Department of Internal Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  13. 13Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  14. 14School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  1. *Corresponding author. Email: kenneth_anderson{at}dfci.harvard.edu
  • These authors contributed equally to this work.

  • Present address: Vertex Pharmaceuticals, 50 Northern Avenue, Boston, MA 02210, USA.

  • § Present address: Department of Hematology and Oncology, Tokai University School of Medicine, Isehara 259-1193, Japan.

Altmetric

Article usage

Article usage: June 2021 to July 2021

AbstractFullPdf
Jun 20211472261796
Jul 2021115415136

Stay Connected to Science Advances

Navigate This Article